Skip to main content

Day: August 22, 2024

Asensus Surgical Announces Closing of Acquisition by KARL STORZ

KARL STORZ acquires US-headquartered company to create a surgical robotics hub and drive Perfomance-Guided Surgery™ RESEARCH TRIANGLE PARK, N.C. and TUTTLINGEN, Germany, Aug. 22, 2024 (GLOBE NEWSWIRE) — Asensus Surgical, Inc. (NYSE American: ASXC) (“Asensus Surgical” or “Asensus”), a global leader of innovative digital solutions for the operating room, today announced the closing of the merger (the “Merger”) with the KARL STORZ Group (“KARL STORZ”). The transaction was completed following approval by the Asensus Surgical stockholders. Under the terms of the merger agreement, KARL STORZ Endoscopy-America, Inc., a wholly owned direct subsidiary of KARL STORZ, has acquired all outstanding shares of Asensus Surgical for $0.35 per share in cash. As a result of the acquisition, Asensus Surgical has become a subsidiary of KARL...

Continue reading

SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

Professor Peled is the Director of the Oncology Department at the Shaare Zedek Medical Center, Jerusalem, Israel, and the head of the Global Multidisciplinary Practice Standards Committee (GMPSC) of the IASLC TEL AVIV, Israel, Aug. 22, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that MitoCareX Bio Ltd. (“MitoCareX”), the Company’s venture with Dr. Alon Silberman that focuses on drug discovery and development of therapeutics for cancer and other life-threatening conditions by targeting the mitochondrial SLC25 protein family, has appointed Professor Nir Peled as a member of its scientific advisory board. Professor...

Continue reading

C3is Inc. reports second quarter and six months 2024 financial and operating results

ATHENS, Greece, Aug. 22, 2024 (GLOBE NEWSWIRE) — C3is Inc. (Nasdaq: CISS) (the “Company”), a ship-owning company providing drybulk and tanker seaborne transportation services, announced today its unaudited financial and operating results for the second quarter and six months ended June 30, 2024. OPERATIONAL AND FINANCIAL HIGHLIGHTSOur handysize dry bulk carriers are on time charters of short term durations, producing steady cash flows, while our Aframax tanker operates in the spot market where voyage charter rates for Aframax tankers are currently around $27,000 per day. All our handysize dry bulk carriers and our Aframax tanker are unencumbered. Fleet operational utilization of 87.7% for the three months ended June 30, 2024, mainly due to the commercial idle days of the vessel that operated in the spot market, as our vessels...

Continue reading

Nexxen Reports Second Quarter 2024 Financial Results

Generated record Q2 Contribution ex-TAC, programmatic revenue and CTV revenue Achieved 27% year-over-year Adjusted EBITDA growth in Q2 2024 while expanding Adjusted EBITDA Margin as a percentage of Contribution ex-TAC to 32% from 26% in Q2 2023 Reaffirming full year 2024 Contribution ex-TAC and Adjusted EBITDA guidance Launched $50 million Ordinary Share repurchase program and fully repaid the Company’s outstanding long-term debt in Q2 2024 NEW YORK, Aug. 22, 2024 (GLOBE NEWSWIRE) — Nexxen International Ltd. (AIM/NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, announced today its financial results for the three and six months ended June 30, 2024. Q2 2024 Financial HighlightsRecord Q2 Contribution ex-TAC of $83.1 million, up 4% year-over-year Record...

Continue reading

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease

PURCHASE, N.Y., Aug. 22, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that results from the SEQUEL study of CT1812, the Company’s lead candidate for the treatment of Alzheimer’s disease, were published in The Journal of Prevention of Alzheimer’s Disease. SEQUEL was a single-site study that measured brain wave patterns in 16 adults with mild-to-moderate Alzheimer’s disease following 29-days of treatment with CT1812 or placebo. In this study, CT1812-treated participants exhibited consistent trends of improvement across all prespecified electroencephalography (EEG) parameters with several reaching significance, including the change in relative theta power in the central region...

Continue reading

Smart Share Global Limited Announces Second Quarter 2024 Results

POIs1 operated through network partner model reached 89.2% as of the end of the second quarter of 2024Cumulative registered users2 reached 417.1 million as of the end of the second quarter of 2024 SHANGHAI, Aug. 22, 2024 (GLOBE NEWSWIRE) — Smart Share Global Limited (Nasdaq: EM) (“Energy Monster” or the “Company”), a consumer tech company providing mobile device charging service, today announced its unaudited financial results for the quarter ended June 30, 2024. HIGHLIGHTS FOR THE SECOND QUARTER OF 2024As of June 30, 2024, 89.2% of POIs were operated under our network partner model, compared with 79.7% as of March 31, 2024. As of June 30, 2024, the Company’s services were available in 1,267 thousand POIs, compared with 1,245 thousand as of March 31, 2024. As of June 30, 2024, the Company’s available-for-use power banks3 were...

Continue reading

BOS Reports Financial Results for the First Half and the Second Quarter of the Year 2024

Net income of $1.2 million and $500,000 in the first half and 2nd quarter of 2024, respectively RISHON LE ZION, Israel, Aug. 22, 2024 (GLOBE NEWSWIRE) — BOS Better Online Solutions Ltd. (“BOS” or the “Company”) (NASDAQ: BOSC) reported its financial results for the second quarter of the year 2024. Eyal Cohen, BOS’ CEO, stated: “Revenues for the first half of year 2024 were lower by 16% than revenues in the comparable period last year. The shortage of electronic components in 2022 prompted the defense sector customers of the Supply Chain division to increase their inventory, which contributed significantly to our revenue growth in 2023. As the component shortage eased in 2023, our defense customers began to reduce their inventory, leading to a dip in our revenues in the first half of 2024. However,...

Continue reading

Peloton Interactive, Inc. Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

NEW YORK, Aug. 22, 2024 (GLOBE NEWSWIRE) — Peloton Interactive, Inc. (Nasdaq: PTON) has announced its financial results for fourth quarter and full year fiscal 2024. Please visit the Peloton investor relations website to view the shareholder letter. Today the company will host a conference call and live audio webcast to discuss the results at 8:30 a.m. ET. Call Details:Event: Peloton Fourth Quarter and Full Year Fiscal 2024 Earnings Conference CallDate: Thursday, August 22, 2024Time: 8:30 a.m. ET Live Call Registration (link) Live Audio Webcast (link) For those unable to participate in the conference call, a replay will be available on the investor relations page of the company’s website for 30 days. About Peloton Peloton (NASDAQ: PTON), provides Members with expert instruction, and world class content to create impactful...

Continue reading

Verano Announces Closing of Acquisition of Arizona and Virginia Subsidiaries of The Cannabist Company, Becomes Exclusive Cannabis Operator for HSA 5 in Eastern Virginia and Strengthens Arizona Footprint

Acquisitions Expand Verano’s Footprint to 14 States, 15 Cultivation and Production Facilities, and 150 Dispensaries Nationwide CHICAGO, Aug. 22, 2024 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the closing of acquisitions pursuant to agreements previously announced on July 29, 2024, and acquired all of the ownership interests of three subsidiaries of The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQX: CBSTF) (“The Cannabist Company”), one of the most experienced cultivators, manufacturers and retailers of cannabis products in the U.S. Two subsidiaries, 203 Organix, L.L.C. and Salubrious Wellness Center, Inc. (together, the “Arizona Operations”) operate in Arizona, and the third subsidiary, Columbia Care Eastern...

Continue reading

Teleflex to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

WAYNE, Pa., Aug. 22, 2024 (GLOBE NEWSWIRE) — Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Morgan Stanley 22nd Annual Global Healthcare Conference at the Marriott Marquis New York, on Friday, September 6, 2024, at 7:45 a.m. (ET). A live audio webcast of the conference presentation will be available on the investor section of the Teleflex website at teleflex.com. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.